Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma

Neuro-Oncology

Volumn 12, Issue 8, 2010, Pages 871-881

  Kunwar, Sandeep ^a   Chang, Susan ^a   Westphal, Manfred ^b   Vogelbaum, Michael ^c   Sampson, John ^d   Barnett, Gene ^c   Shaffrey, Mark ^e   Ram, Zvi ^f   Piepmeier, Joseph ^g   Prados, Michael ^a   Croteau, David ^h   Pedain, Christoph ⁱ   Leland, Pamela ^j   Husain, Syed R ^j   Joshi, Bharat H ^j   Puri, Raj K ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c LERNER RESEARCH INSTITUTE   (United States)

^d DUKE UNIVERSITY   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NeoPharm Inc   (United States)

ⁱ BrainLAB   (Germany)

^j CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

more..

Author keywords

Cintredekin besudotox; Convection enhanced delivery; Gliadel wafers; Glioblastoma multiforme; IL13 PE38QQR

Indexed keywords

CARMUSTINE; CINTREDEKIN BESUDOTOX; EXOTOXIN; INTERLEUKIN 13; ANTINEOPLASTIC AGENT; DECANEDIOIC ACID 4,4' (1,3 PROPANEDIYLBIS(OXY))BIS(BENZOIC ACID) COPOLYMER; DECANEDIOIC ACID-4,4'-(1,3-PROPANEDIYLBIS(OXY))BIS(BENZOIC ACID) COPOLYMER; DECANOIC ACID DERIVATIVE; IL13-PE38QQR; POLYESTER;

ADULT; APHASIA; ARTICLE; BRAIN EDEMA; CANCER GRADING; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COORDINATION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GAIT DISORDER; GLIOBLASTOMA; HEMIPARESIS; HEMIPLEGIA; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MONOPARESIS; OVERALL SURVIVAL; PARESIS; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; ADOLESCENT; AGED; BRAIN TUMOR; DRUG ADMINISTRATION ROUTE; INDWELLING CATHETER; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; THERMODYNAMICS; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CATHETERS, INDWELLING; CONVECTION; DECANOIC ACIDS; DRUG ADMINISTRATION ROUTES; EXOTOXINS; FEMALE; GLIOBLASTOMA; HUMANS; INTERLEUKIN-13; KAPLAN-MEIERS ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYESTERS; YOUNG ADULT;

EID: 78149479157     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop054     Document Type: Article

References (38)

1. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;345:1008-1012.
2. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA. 1994;91:2076-2080.
3. Chen MY, Lonser RR, Morrison PF, Governale LS, Oldfield EH. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg. 1999;90:315-320.
4. Laske DW, Morrison PF, Lieberman DM, et al. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg. 1997;87:586-594.
5. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg. 1995;82:1021-1029.
6. Morrison PF, Chen MY, Chadwick RS, Lonser RR, Oldfield EH. Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol. 1999;277: R1218-R1229.
7. Morrison PF, Laske DW, Bobo H, Oldfield EH, Dedrick RL. High-flow microinfusion: tissue penetration and pharmacodynamics. Am J Physiol. 1994;266:R292-R305.
8. Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg. 2004;101:1004-1011.
9. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl. 2003;88:105-111.
10. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg. 2004;100:472-479.
11. Sampson JH, Akabani G, Archer GE, et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003;65:27-35.
12. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65:3-13.
13. Weber F, Asher A, Bucholz R, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol. 2003;64:125-137.
14. Kawakami M, Kawakami K, Puri RK. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther. 2002;1:999-1007.
15. Kawakami M, Kawakami K, Puri RK. Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways. Int J Cancer. 2003;103:45-52.
16. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res. 1999;5:985-990. (Pubitemid 29233211)
17. Debinski W, Miner R, Leland P, Obiri NI, Puri RK. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J Biol Chem. 1996;271: 22428-22433.
18. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res. 1995;1:1253-1258.
19. Joshi BH, Plautz GE, Puri RK. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. Cancer Res. 2000;60:1168-1172.
20. Liu H, Jacobs BS, Liu J, et al. Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol Immunother. 2000;49:319-324.
21. Husain SR, Joshi BH, Puri RK. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer. 2001;92: 168-175.
22. Kunwar S, Prados MD, Chang SM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol. 2007;25:837-844.
23. Joshi BH, Puri RK. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Protein Expr Purif. 2005;39:189-198.
24. Parney IF, Kunwar S, McDermott M, et al. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg. 2005;102:267-275.
25. Vogelbaum MA. Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J Neurooncol. 2007;83:97-109.
26. Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res. 2007;67:7983-7986.
27. Saikali S, Avril T, Collet B, et al. Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol. 2007;81:139-148.
28. Reznick RK. Teaching and testing technical skills. Am J Surg. 1993;165:358-361.
29. Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics. 2008;5:123-127.
30. Krauze MT, Forsayeth J, Park JW, Bankiewicz KS. Real-time imaging and quantification of brain delivery of liposomes. Pharm Res. 2006;23:2493-2504.
31. Sampson JH, Brady ML, Petry NA, et al. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery. 2007;60:ONS89-ONS98; discussion ONS98-ONS99.
32. Sampson JH, Raghavan R, Brady ML, et al. Clinical utility of a patientspecific algorithm for simulating intracerebral drug infusions. Neuro-Oncology. 2007;9:343-353.
33. Lonser RR, Schiffman R, Robison RA, et al. Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease. Neurology. 2007;68:254-261.
34. Voges J, Reszka R, Gossmann A, et al. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann Neurol. 2003;54:479-487.
35. Perlstein B, Ram Z, Daniels D, et al. Convection-enhanced delivery of maghemite nanoparticles: increased efficacy and MRI monitoring. Neuro-Oncology. 2008;10:153-161.
36. Yin D, Valles FE, Fiandaca MS, et al. Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage. 2009; doi:10.1016/j.neuroimage.2009.08.069. Epub ahead of print September 15, 2009.
37. Fadul C, Wood J, Thaler H, Galicich J, Patterson RH, Jr, Posner JB. Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology. 1988;38:1374-1379.
38. Sawaya R, Hammoud M, Schoppa D, et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998;42:1044-1055; discussion 1055-1056.